MedPath

Nutrition Intervention in Treating Women With Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
Registration Number
NCT00002564
Lead Sponsor
Institute for Cancer Prevention (IFCP)
Brief Summary

RATIONALE: Dietary fat may be involved in the growth of cancer cells. Restricting dietary fat may help fight cancer.

PURPOSE: Randomized clinical trial to study the effectiveness of a low fat diet in treating postmenopausal women who have stage I, stage II, or stage IIIA breast cancer that has been completely removed by surgery.

Detailed Description

OBJECTIVES: I. Determine whether dietary fat reduction will effectively prolong disease-free and overall survival in women surgically treated for early stage breast cancer who are receiving adjuvant therapy with or without either tamoxifen, cyclophosphamide, methotrexate, fluorouracil (CMF), doxorubicin, cyclophosphamide (AC), fluorouracil, doxorubicin, cyclophosphamide (FAC, CAF), or AC followed by paclitaxel. II. Evaluate whether differences in the lipid profile are associated with dietary group assignment and dietary fat.

OUTLINE: This is a randomized, multicenter study. Patients are stratified by center, nodal status, ER status, and type of adjuvant chemotherapy. The first group receives intensive dietary intervention for reduction of total fat intake to 15% of calories, with repeated individual and group counseling sessions. The second group receives USDA/DHHS dietary guidelines and minimal intervention. All patients who are estrogen receptor positive receive concurrent therapy with tamoxifen; cyclophosphamide, methotrexate, fluorouracil (CMF) followed by tamoxifen; doxorubicin, cyclophosphamide (AC) followed by tamoxifen; fluorouracil, doxorubicin, cyclophosphamide (FAC, CAF) followed by tamoxifen; or AC, paclitaxel followed by tamoxifen. Patients are followed annually throughout the study.

PROJECTED ACCRUAL: Approximately 2,500 women will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
2500
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (37)

Memorial Sloan-Kettering Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Cedars-Sinai Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Palm Beach Oncology-Hematology at the Good Samaritan Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

West Palm Beach, Florida, United States

St. Barnabas Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Livingston, New Jersey, United States

North Shore University Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Manhasset, New York, United States

Geisinger Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Danville, Pennsylvania, United States

Cancer Research Center of Hawaii

๐Ÿ‡บ๐Ÿ‡ธ

Honolulu, Hawaii, United States

University of Alabama Comprehensive Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Birmingham, Alabama, United States

Virginia Piper Cancer Institute

๐Ÿ‡บ๐Ÿ‡ธ

Minneapolis, Minnesota, United States

Sylvester Cancer Center, University of Miami

๐Ÿ‡บ๐Ÿ‡ธ

Miami, Florida, United States

Barbara Ann Karmanos Cancer Institute

๐Ÿ‡บ๐Ÿ‡ธ

Detroit, Michigan, United States

Duke Comprehensive Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Durham, North Carolina, United States

John Wayne Cancer Institute

๐Ÿ‡บ๐Ÿ‡ธ

Santa Monica, California, United States

Arizona Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Tucson, Arizona, United States

Baptist Regional Cancer Institute - Jacksonville

๐Ÿ‡บ๐Ÿ‡ธ

Jacksonville, Florida, United States

Women to Women

๐Ÿ‡บ๐Ÿ‡ธ

Yarmouth, Maine, United States

Chao Family Comprehensive Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Orange, California, United States

Sharp Healthcare - Murrieta

๐Ÿ‡บ๐Ÿ‡ธ

Murrieta, California, United States

Bennett Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Stamford, Connecticut, United States

Evanston Northwestern Health Care

๐Ÿ‡บ๐Ÿ‡ธ

Evanston, Illinois, United States

Fred Hutchinson Cancer Research Center

๐Ÿ‡บ๐Ÿ‡ธ

Seattle, Washington, United States

Lombardi Cancer Center, Georgetown University

๐Ÿ‡บ๐Ÿ‡ธ

Washington, District of Columbia, United States

Texas Oncology, P.A.

๐Ÿ‡บ๐Ÿ‡ธ

Dallas, Texas, United States

Jonsson Comprehensive Cancer Center, UCLA

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Permanente Medical Group (060)

๐Ÿ‡บ๐Ÿ‡ธ

Oakland, California, United States

Shands Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Gainesville, Florida, United States

Midwestern Regional Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Zion, Illinois, United States

Beth Israel Deaconess Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

University of Iowa Hospitals and Clinics

๐Ÿ‡บ๐Ÿ‡ธ

Iowa City, Iowa, United States

American Health Foundation

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Surgical Associates

๐Ÿ‡บ๐Ÿ‡ธ

Albuquerque, New Mexico, United States

Arthur G. James Cancer Hospital - Ohio State University

๐Ÿ‡บ๐Ÿ‡ธ

Columbus, Ohio, United States

Kaiser Permanente Center for Health Research

๐Ÿ‡บ๐Ÿ‡ธ

Portland, Oregon, United States

Spohn Hospital South

๐Ÿ‡บ๐Ÿ‡ธ

Corpus Christi, Texas, United States

Medical University of South Carolina

๐Ÿ‡บ๐Ÿ‡ธ

Charleston, South Carolina, United States

Medical College of Wisconsin

๐Ÿ‡บ๐Ÿ‡ธ

Milwaukee, Wisconsin, United States

Rhode Island Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Providence, Rhode Island, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath